In yesterday’s Wall Street session, Tenax Therapeutics Inc (NASDAQ:TENX) shares traded at $0.50, down -18.55% from the previous session.
1 analysts cover Tenax Therapeutics Inc (NASDAQ:TENX), according to research data. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $6.00 and a low of $5.00, we find $5.50. Given the previous closing price of $0.62, this indicates a potential upside of 787.1 percent. TENX stock price is now 81.49% away from the 50-day moving average and 15.40% away from the 200-day moving average. The market capitalization of the company currently stands at $12.05M.
The stock has received a hold rating from 0 analysts and a buy rating from 1. Brokers who have rated the stock have averaged $5.50 as their price target over the next twelve months.
A total of 2.33% of the company’s stock is owned by insiders.
On Tuesday morning Tenax Therapeutics Inc (NASDAQ: TENX) stock kicked off with the opening price of $0.5096. During the past 12 months, Tenax Therapeutics Inc has had a low of $0.15 and a high of $4.30. As of last week, the company has a debt-to-equity ratio of 0.02, a current ratio of 19.73, and a quick ratio of 19.73. The fifty day moving average price for TENX is $0.2782 and a two-hundred day moving average price translates $0.4376 for the stock.
The latest earnings results from Tenax Therapeutics Inc (NASDAQ: TENX) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at -$0.05, beating analysts’ expectations of -$0.1 by 0.05. This compares to -$2.13 EPS in the same period last year. The company reported revenue of $2.12 million for the quarter, compared to $2.92 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -27.45 percent.
Tenax Therapeutics Inc(TENX) Company Profile
Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension. It develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.